Written by the leading melanoma experts from the United States, Australia, and Europe, this new edition incorporates the clinical outcomes of more than 70,000 patients treated at major melanoma centers throughout the world and is the definitive and most authoritative textbook on melanoma used worldwide. Providing the most up-to-date and comprehensive information needed for the clinical management and scientific study of melanoma, Cutaneous Melanoma, 6th edition covers everything from precursors of melanoma to advanced stages of metastatic disease.
Biology of Melanocytes and Primary Melanoma.- Immunology of Melanoma.- Biomarkers for Melanoma.- Clinical Presentations of Melanoma.- Dermoscopy/Confocal Microscopy.- Biopsy of Suspected Melanoma.- Lymphoscintigaphy in Patients With Melanoma.- Biopsy of the Sentinel Lymph Node.- Melanoma Prognosis and Staging.- Models for Predicting Melanoma Outcome.- Classification and Histopathology of Melanoma .- Molecular Pathology and Genomics of Melanoma.- Clinical Epidemiology of Melanoma.- Molecular Epidemiology of Melanoma.- Clinical Genetics and Risk Assessment of Melanoma.- Acquired Precursor Lesions and Phenotypic Markers of Increased Risk for Cutaneous Melanoma.- Melanoma Prevention and Screening.- Treatment of Primary Melanoma.- Reconstructive Options Following Surgery of Primary Melanoma.- Axillary and Epitrochlear Lymph Node Dissection for Melanoma.- Inguinofemoral, Iliac/Obturator, and Popliteal Lymphadenectomy for Melanoma.- Neck Dissection and Parotidectomy for Melanoma.- Local and Recurrent Regional Metastases of Melanoma.- Radiotherapy for Primary and Regional Melanoma.- Adjuvant Systemic Therapy for High-Risk Melanoma Patients.- Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients.- Hyperthermic Regional Perfusion for Melanoma of the Limbs.- Isolated Limb Infusion for Melanoma.- Surveillance and Follow-up of Melanoma Patients.- Local melanoma recurrence, satellitosis and in transit metastasis: incidence, outcomes and selection of treatment options .- Acral Lentiginous Melanoma.- Lentigo Maligna Melanoma.- Mucosal Melanoma.- Melanoma in Children and Teenagers.- Pregnancy and the Use of Hormones in Melanoma Patients.- Diagnosis of Stage IV Melanoma.- Evolving Role of Chemotherapy-Based Treatment of Metastatic Melanoma.- Targeted Therapies for BRAF Mutant Metastatic Melanoma.- Molecularly Targeted Therapy for Patients With BRAF Wild-type Melanoma.- Cytokines (IL-2, IFN GM-CSF etc) Melanoma.- Checkpoint Inhibitors in the Treatment of Metastatic Melanoma.- Novel Immunotherapies and Novel Combinations of Immunotherapy.- Managing Checkpoint Inhibitor Symtoms and Toxicity.- Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma.- Melanoma Vaccines.- Cellular Therapy for Melanoma.- Systemic Therapy for Mucosal, Acral and Uveal Melanoma.- Dermatological Complications of Systemic Therapies for Melanoma.- Surgical Management of Distant Melanoma Metastases.- Radiotherapy for Distant Metastases.- Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy.- A History of Melanoma: From Hunter to Morton.
Dr. Charles M. Balch, M.D., FACS, Professor of Surgery, University of Texas Southwestern Medical Center, was previously Deputy Director for Clinical Trials and Outcomes Research at Johns Hopkins Institute and Executive Vice President and Chief Executive Officer of American Society of Clinical Oncology (ASCO). He has led a distinguished career as a clinical and academic oncologist for the past 35 years, as a leading authority in both melanoma and breast cancer. He has also made significant contributions to laboratory research in tumor immunology and human T lymphocyte differentiation. He is author of over 700 publications, which have been cited over 20,000 times in the biomedical literature, and has lectured in over 35 different countries in the world and most of the major academic centers in the United States. Dr. Balch is the founding Editor-in-Chief of the Annals of Surgical Oncology (Springer), which is recognized as the leading journal in the world in its field. He also held major leadership roles involving clinical research in three comprehensive cancer centers (University of Alabama at Birmingham, University of Texas M D Anderson, and the City of Hope National Medical center).
John Thompson, MD, Melanoma Institute of Australia, Surgical Oncology
Michael Atkins, MD, Georgetown Medical Center, Medical Oncology
John Kirkwood, MD, University of Pittsburgh, Medical Oncology
Arthur Sober, MD, Harvard Medical Center, Dermatology
Allan Halpern, MD, Memorial Sloan Kettering, Dermatology
Claus Garbe, University Hospital, Tuebingen, Dermatology
Offers complete coverage from precursors to advance stages
Explores the risks and benefits of each treatment modality
Incorporates clinical outcomes of more than 70,000 patients